Improving outcomes for R/R DLBCL with polatuzumab vedotin

Improving outcomes for R/R DLBCL with polatuzumab vedotin

VJHemOnc

1 year
86 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Patients with relapsed, transplant ineligible diffuse large B-cell lymphoma (DLBCL) face extremely poor outcomes. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Marek Trneny, MD, PhD, of Charles University, Prague, Czech Republic, discusses a recent trial (NCT02257567) that aimed to improve care for these patients using a combination therapy of bendamustine, rituximab and the antibody-drug conjugate polatuzumab vedotin. The positive survival data from this study suggest a new treatment avenue for patients who previously had few options.
Up Next Autoplay